Product image of Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po) supplied by GNH India

Imovax Polio

Active Ingredient:
Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po
Origin:
EU

Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

Inactivated poliovirus vaccine, the active ingredient in Imovax Polio, is a vaccine presented as an injectable solution for intramuscular, subcutaneous use. It is used to prevent poliomyelitis in individuals at risk of exposure.

GNH India supplies Imovax Polio as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sanofi Winthrop Industrie

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imovax Polio is a vaccine indicated for preventing poliovirus infection and its complications. It is employed in several clinical contexts:

  • Poliomyelitis (polio): Induces protective immunity against poliovirus types 1, 2 and 3 to prevent infection and disease.
  • Travel to endemic regions: Provides immunity before exposure for travelers visiting areas with circulating poliovirus.
  • Outbreak response: Used in mass vaccination campaigns to halt transmission during poliovirus outbreaks.

How It Works

  • Imovax Polio contains inactivated poliovirus types 1, 2 and 3. After intramuscular or subcutaneous injection, the viral antigens are taken up by antigen‑presenting cells, stimulating B‑cell production of neutralising antibodies and activating T‑cell help. The resulting humoral response confers active immunity that blocks viral replication and prevents paralytic disease.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Fever: low‑grade temperature rise within 24‑48 hours.
  • Headache: transient headache post‑vaccination.
  • Malaise: general feeling of tiredness.
  • Muscle aches: mild myalgia.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare autoimmune neuropathy.
  • Seizures: uncommon neurologic event.
  • High fever: temperature >39°C persisting beyond 48 hours.
  • Hypotension: sudden drop in blood pressure.
  • Severe allergic reaction to vaccine components.

Precautions & Warnings

Before administering Imovax Polio, consider the following precautions:

  • Pregnancy: consult a healthcare professional; benefits should outweigh potential risks.
  • Breastfeeding: use with caution; discuss with a physician.
  • Immunocompromised patients: monitor immune response, although the vaccine is inactivated.
  • Allergies: avoid if the patient has a known severe allergy to any vaccine component.
  • Administration technique: ensure correct intramuscular or subcutaneous injection using aseptic method.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Imovax Polio may interact with other agents that affect immune response.

Major Interactions (Avoid)

  • Live attenuated vaccines: avoid simultaneous administration; separate by at least 4 weeks.
  • Immunoglobulin therapy: may diminish vaccine‑induced immunity.

Moderate Interactions (Monitor Closely)

  • Antipyretics (e.g., acetaminophen): may mask fever, monitor for underlying reactions.
  • Corticosteroids: high‑dose therapy may blunt antibody production.
  • Blood products: transfusions shortly after vaccination could affect immune response.
  • Other vaccines: schedule appropriately to avoid interference.

Frequently Asked Questions

Imovax Polio is an inactivated poliovirus vaccine indicated for the prevention of poliomyelitis. It stimulates the immune system to produce neutralising antibodies against poliovirus types 1, 2 and 3, thereby protecting individuals from infection and the associated paralytic disease.

The vaccine contains chemically inactivated poliovirus particles that cannot cause disease. After injection, the immune system recognises the viral antigens, activates B‑cells to produce neutralising antibodies, and engages T‑cell help, establishing active immunity that blocks future poliovirus infection.

The dosing schedule for Imovax Polio is determined by the prescribing healthcare professional based on age, vaccination history, and regional guidelines. The prescriber selects the appropriate number of doses and intervals to achieve optimal immunity.

Safety data for Imovax Polio in pregnancy are limited, so it should be administered only if the potential benefit justifies any potential risk. Breastfeeding is not a contraindication, but mothers should discuss use with their healthcare provider to weigh benefits and risks.

To order Imovax Polio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Imovax Polio is an inactivated (killed) vaccine, whereas some alternatives, such as oral polio vaccine (OPV), contain live attenuated virus. Inactivated vaccines cannot cause vaccine‑derived poliovirus infection and are preferred in settings where OPV risks are a concern, though both aim to induce protective immunity.

Imovax Polio must be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

The vaccine is given by intramuscular or subcutaneous injection, typically into the deltoid muscle or anterolateral thigh in infants. Administration should follow aseptic technique, using the appropriate needle size and volume as directed by the prescriber.

Serious adverse events are rare but may include anaphylaxis, Guillain‑Barré syndrome, high‑grade fever, seizures, and severe allergic reactions to vaccine components. Any signs of a severe reaction require immediate medical evaluation.

Individuals with a known severe allergy to any component of the vaccine, or who have experienced a previous severe reaction to an inactivated poliovirus vaccine, should not receive Imovax Polio. Contraindications should be confirmed by a qualified healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT